同步放化疗治疗老年食管癌的安全性评价及近期疗效分析  

Safety Evaluation and Short-term Efficacy Analysis of Concurrent Chemoradiotherapy in the Treatment of Elderly Esophageal Cancer

作　　者：张瑶瑶 陈东基 胡芳霞 ZHANG Yaoyao;CHEN Dongji;HU Fangxia(Department of Radiotherapy,Wuwei Cancer Hospital of Gansu Province,Wuwei,Gansu,733000,China;Depart-ment of Oncology,Wuwei People's Hospital of Gansu Province,Wuwei,Gansu,733000,China)

机构地区：[1]甘肃省武威肿瘤医院放疗科,甘肃武威733000 [2]甘肃省武威市人民医院肿瘤内科,甘肃武威733000

出　　处：《中外医疗》2025年第5期53-57,共5页China & Foreign Medical Treatment

摘　　要：目的探讨同步放化疗治疗老年食管癌的安全性及近期疗效。方法随机选取2021年4月—2023年4月甘肃省武威肿瘤医院收治的80例老年食管癌患者为研究对象,依据治疗方案不同分为两组,各40例,对照组单纯采用放疗方案,研究组采用同步放化疗方案。对比两组临床疗效、免疫功能、炎性因子水平、不良反应。结果与对照组治疗总有效率[52.50%(21/40)]比较,研究组的75.00%(30/40)更高,差异有统计学意义(χ^(2)=4.381,P<0.05)。与治疗前比较,两组患者治疗后的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)指标均较高,CD8^(+)指标较低,且研究组优于对照组,差异均有统计学意义(P均<0.05)。血清炎性因子(白细胞介素-6、白细胞介素-8、肿瘤坏死因子-α)水平方面,两组患者治疗后比较,研究组较低,差异均有统计学意义(P均<0.05)。不良反应总发生率方面,两组比较,差异无统计学意义(P>0.05)。结论对老年食管癌患者应用同步放化疗治疗,可取得更为理想的治疗效果,利于改善患者免疫功能及减轻机体炎性反应,并未增加不良反应。Objective To explore the safety and short-term efficacy of concurrent chemoradiotherapy in the treatment of elderly esophageal cancer.Methods Eighty elderly patients with esophageal cancer admitted to Wuwei Cancer Hospital of Gansu Province from April 2021 to April 2023 were randomly selected as the research objects.According to different treatment regimens,they were divided into two groups,with 40 cases in each group.The control group was treated with radiotherapy alone,and the study group was treated with concurrent chemoradiotherapy.The clinical efficacy,immune function,levels of inflammatory factors and adverse reactions were compared between the two groups.Results Compared with 52.50%(21/40)in the control group,the total effective rate 75.00%(30/40)of the study group was higher,and the difference was statistically significant(χ^(2)=4.381,P<0.05).Compared with before treatment,the indexes of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)were higher in both groups after treatment,while the indexes of CD8^(+)was lower,and the study group were better than the control group,and the differences were statistically significant(all P<0.05).The levels of serum inflammatory factors(interleukin-6,interleukin-8,tumor necrosis factor-α)were compared in the two groups after treatment,and the study group were lower,and the differences were statistically significant(all P<0.05).In terms of the total incidence of adverse reactions,there was no significant difference between the two groups(P>0.05).Conclusion The application of concurrent chemoradiotherapy in elderly patients with esophageal cancer can achieve more satisfactory treatment results,which is beneficial to improving the immune function of patients and reducing the inflammatory response of the body.Moreover,the treatment method does not increase the occurrence of adverse reactions.

关 键 词：食管癌 老年 同步放化疗治疗 免疫功能 炎性因子水平 不良反应 

分 类 号：R735.1[医药卫生—肿瘤]